The benefits associated with Allergan Plc’s experimental drug to treat frequent nightly urination outweigh the risks for certain patients, an advisory panel to the U.S. Food and Drug Administration concluded.
The U.S. Food and Drug Administration granted accelerated approval to Eli Lilly and Co.’s drug for treating adults with advanced soft tissue sarcoma (STS).
The U.S. Health and Human Services Department estimates that 1 million more people will sign up for health insurance on the Obamacare exchanges for 2017 compared with 2016, a department official told reporters.
Abbott Laboratories reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.
Merck & Co.’s experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in late-stage trial.
Despite Bashing the Pharma Industry, More Than Half of Biotech Execs Surveyed Still Support Hillary Clinton
Despite calls for curbing high drug prices and criticisms over executive salaries, Hillary Clinton seems to have the most support from pharmaceutical executives, according to a recent survey of 100 biotech executives conducted by Endpoints.
Daiichi Sankyo of Tokyo and Berkeley, California-based Plexxikon recently suspended recruitment of people in its Phase III ENLIVEN clinical trial in patients with a giant cell tumor of the tendon sheath.
Swiss drugmaker Roche Holding’s new immunotherapy Tecentriq won approval from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb’s position in this hotly contested market.
U.S. health officials outlined how they planned to divide up $1.1 billion in funds approved by Congress to fight the Zika virus, including repaying $44.25 million they were forced to borrow from a fund allocated for other emergencies.
Abbott, which is in the process of buying St. Jude Medical, said the companies would sell some medical devices to Japan-based Terumo for about $1.12 billion.
Eli Lilly and Company announced an ambitious plan to increase access to quality health care and to improve long-term health for millions of people worldwide.
When former President Bill Clinton called parts of Obamacare “crazy,” he put his wife Hillary Clinton on the defensive and gave much-needed ammunition to her Republican rival for the presidency, Donald Trump, who wants to scrap it.
Hollywood loves to feed the movie-going public with stories about big bad companies. Evil, greedy companies are an easier sell for Hollywood. And given all of the controversy over drug pricing in the news this election season, it will be a long time coming before there is a positive film about a life science company. There surely will be plenty of new movies to come that look negatively at the life sciences industry.
Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.
U.S. Vice President Joseph Biden’s Cancer Moonshot initiative to speed the development of cancer treatments has made some important strides, but still faces challenges in many areas according to a report.
A New York fertility specialist, who said he successfully carried out a “three-parent” in vitro fertilization (IVF) technique resulting in a baby boy, called the procedure a “revolutionary approach in human reproduction.
Omnicare Inc., the largest nursing home pharmacy in the United States, will pay about $28.1 million to resolve civil charges that it sought and received kickbacks from Abbott Laboratories to promote the drug maker’s anti-seizure drug Depakote, the U.S. Justice Department said.
Proposed dosing for a drug being developed by Allergan to treat frequent urination at night has been inadequately studied in trials, per an FDA preliminary review.
PepsiCo Inc. has set a target for reducing the amount of sugar in its soft drinks around the world as part of a suite of goals aimed at tackling problems ranging from obesity to climate change.
Regeneron and partner Teva said the U.S. health regulator placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.